Velarion · Company Intelligence
CompBrief
Fiscal year 2025

Rick Winningham — FY2025 total compensation $1,472,019

Rick Winningham is Chief Executive Officer of Theravance Biopharma, Inc. (TBPH). The company reported total compensation of $1,472,019 for fiscal year 2025.

01

Fiscal year 2025 compensation

Salary$1,047,431
Bonus$0
Stock awards$0
Option awards$0
Non-equity incentive plan$419,182
Pension and non-qualified deferred compensation$0
All other compensation$5,406
Total$1,472,019

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.

Cited to the compensation disclosure Theravance Biopharma, Inc. filed April 28, 2026, accession 0001104659-26-050454.

02

History — every fiscal year held

Fiscal yearRoleSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
FY2025Chief Executive Officer$1,047,431$0$0$0$419,182$0$5,406$1,472,019
FY2024Chief Executive Officer$1,047,431$9,802$2,443,500$0$490,198$0$5,000$3,995,931

Totals as disclosed in each year's own compensation disclosure for Theravance Biopharma, Inc..

04

The other named executive officers of Theravance Biopharma, Inc.

Named executive officerRoleFY2025 total
Rick Winningham this pageChief Executive Officer$1,472,019
Aine MillerSenior Vice President, Development and Head of Ireland Office$1,448,573
Rhonda FarnumChief Business Officer and Senior Vice President, Commercial & Medical Affairs$1,384,192

The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Theravance Biopharma, Inc. compensation brief.

05

The company page

Rick Winningham's compensation sits inside Theravance Biopharma, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.

The Theravance Biopharma, Inc. (TBPH) compensation brief